ESVS 2025 Guidelines
Applied
Type
AdditionConfidence
95%
Created
Mar 17, 2026
Evidence
1 source
Rationale
The section was expanded to include specific clinical details from the ESVS 2025 guidelines regarding the management of mesenteric venous thrombosis. While Article 2 (PMID 28359440) was provided, it represents the 2017 guidelines (despite the 2026 metadata label) and is superseded by the 2025 update in this specific section. The existing citation key European Society for Vascular Surgery (ESVS) was maintained and reinforced with the new metadata from Koelemay et al. (2025).
Evidence
Verified source
Content Changes
removedadded
### ESVS 2025 Guidelines For mesenteric venous thrombosis,thrombosis (MVT), immediate anticoagulation is indicated, with invasivelow-molecular-weight heparin (LMWH) recommended as first-line therapy (thrombolysisin the acute phase [@esvs2025]. Invasive therapy (including catheter-directed thrombolysis or mechanical thrombectomy) should be considered in patients with clinical deterioration or signs of bowel ischemia despite anticoagulation [@esvs2025]. Evaluation for severeunderlying casesprovoking factors (including thrombophilia and malignancy) is recommended. Anticoagulation is generally continued for at least 6 months, with clinicalextended deterioration.or [@esvs2025]indefinite therapy considered for unprovoked MVT or persistent risk factors after individualized bleeding-risk assessment [@esvs2025].
Reviewer Notes
Approved with edits: normalized citation to existing key @esvs2025, clarified long-term anticoagulation as individualized bleeding-risk decision, removed duplicate staged citation key.